Opinion

Video

Combination Therapies for MF Management

Author(s):

Gabriella Hobbs, MD,Andrew Kuykendall, MD

Panel experts comment on the role of combination therapies in MF and debate if these therapies will be the new standard of care.

Related Videos
Naval G. Daver, MD,
Anthony M. Hunter, MD
Craig Eckfeldt, MD
Ann S. LaCasce, MD, MMSc
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on factors for frontline treatment in adult and pediatric acute lymphoblastic leukemia.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Ashkan Emadi, MD, PhD
Peter Riedell, MD
Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Related Content
US FDA
January 16th 2025

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Michael T. Tees, MD, MPH, of Colorado Blood Cancer Institute
January 12th 2025

BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Naseema Gangat, MBBS, of Mayo Clinic
January 10th 2025

Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm

Fonotinib Maleate in Myelofibrosis | Image Credit: LASZLO © stock.adobe.com
January 7th 2025

Flonoltinib Maleate Provides Durable Spleen Reduction and Symptom Improvement in Myelofibrosis